Swarup Kumar Patnaik
Research Subjects
Research Interests
Swarup Kumar Patnaik has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Girish Kumar Pati
Professor, Department of Gastroenterology, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India
2 shared publications - Jimmy Narayan
Department of Gastroenterology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, India
2 shared publications Anirudh Karanam
1 shared publication- Ayaskanta Singh
SUM Ultimate Medicare, Bhubaneswar, India
1 shared publication - Debakanta Mishra
Department of Gastroenterology and Hepatobiliary Sciences, IMS and SUM Hospital, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India
1 shared publication - Kanishka Uthansingh
Multi-Speciality Research Unit, KIMS Cancer Center, KIMS Hospital, KIIT University
1 shared publication
Latest Publications
- 24 July 2023
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 13, S27
In Predicting Esophageal Varices, How Precise Is Platelet Count/Spleen Diameter?
- 24 July 2023
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 13, S27
In Predicting Esophageal Varices, How Precise Is Platelet Count/Spleen Diameter?
- Open Access
- 2 October 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (4) , 2103-2116
Molecular Docking of Anti Helicobacter pylori Antibiotics and Proton Pump Inhibitor: A Single Center Survey
Helicobacter pylorus (H. pylori) is a deadly bacterium responsible for significant worldwide Gastric Cancer (GC) related mortality. The present study aimed to screen all the anti-microbial drugs used to eradicate H .pylori infection and to identify the most efficient drug by using computational methods through molecular docking analysis. The 3-D structure of protein chorismate synthase of H. pylori was downloaded from the Protein data bank (PDB) online browser. The x-ray crystallography structures of 13 common drugs used against H.pylori infection were also downloaded from the drug bank. We screened all 13 common drugs through molecular docking to know the most efficient binding interaction between the diverse ligand-protein complexes. The results were further compared with clinical survey data from the patients with diverse gastrointestinal H. pylori infected cases. Among the screened compounds, by in-silico approach we found that fluoroquinolone (FLRQ) and tetracycline (TET) manifested more significant interactions with chorismate synthase (CS) protein along with binding energies of -9.2 and -8.1 kcal/mole respectively. Further, the drugs were also corroborated with the survey data from patients with varied gastrointestinal disorders in our study. With this computational study, we could find FLRQ and TET may be the most efficient drug for H. pylori treatment, which can be tried in case of anti H. Pylori treatment failure due to resistance. Hence, effective inter-analysis between the experimental and computational approaches is crucial to build up a strong inhibitor.
- 2 October 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (4) , 2103-2116
Open AccessMolecular Docking of Anti Helicobacter pylori Antibiotics and Proton Pump Inhibitor: A Single Center Survey
Helicobacter pylorus (H. pylori) is a deadly bacterium responsible for significant worldwide Gastric Cancer (GC) related mortality. The present study aimed to screen all the anti-microbial drugs used to eradicate H .pylori infection and to identify the most efficient drug by using computational methods through molecular docking analysis. The 3-D structure of protein chorismate synthase of H. pylori was downloaded from the Protein data bank (PDB) online browser. The x-ray crystallography structures of 13 common drugs used against H.pylori infection were also downloaded from the drug bank. We screened all 13 common drugs through molecular docking to know the most efficient binding interaction between the diverse ligand-protein complexes. The results were further compared with clinical survey data from the patients with diverse gastrointestinal H. pylori infected cases. Among the screened compounds, by in-silico approach we found that fluoroquinolone (FLRQ) and tetracycline (TET) manifested more significant interactions with chorismate synthase (CS) protein along with binding energies of -9.2 and -8.1 kcal/mole respectively. Further, the drugs were also corroborated with the survey data from patients with varied gastrointestinal disorders in our study. With this computational study, we could find FLRQ and TET may be the most efficient drug for H. pylori treatment, which can be tried in case of anti H. Pylori treatment failure due to resistance. Hence, effective inter-analysis between the experimental and computational approaches is crucial to build up a strong inhibitor.